Association of angiogenic factors with prognosis in esophageal cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Dreikhausen, Lena ^a   Blank, Susanne ^a   Sisic, Leila ^a   Heger, Ulrike ^a   Weichert, Wilko ^a   Jäger, Dirk ^a   Bruckner, Thomas ^a   Giese, Natalia ^a   Grenacher, Lars ^b   Falk, Christine ^c   Ott, Katja ^a   Schmidt, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Angiogenic factors; Esophageal cancer; Prognosis; Response

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 2; CD31 ANTIGEN; CISPLATIN; EPIRUBICIN; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; FOLLISTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LEPTIN; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN; FST PROTEIN, HUMAN; HGF PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION; ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION; ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR REGRESSION GRADE; ADENOCARCINOMA; AGED; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FOLLOW UP; METABOLISM; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLISTATIN; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84928745681     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1120-5     Document Type: Article

References (41)

1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400-12.
2. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17(1):38-44.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241-52.
4. Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
5. van Hagen PHM, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPRD, Nieuwenhuijzen GA, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
6. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681-92.
7. Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, et al. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg. 2012;398(2):211-20.
8. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719-25.
9. Brucher BL, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30(9):963-71.
10. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441-54.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353-64.
13. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer. 2010;1(1):12-25.
14. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61(3):253-70.
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-42.
16. Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16(6):844-58.
17. Oshima Y, Yajima S, Yamazaki K, Matsushita K, Tagawa M, Shimada H. Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma. Ann Thorac Cardiovasc Surg. 2010;16(6):389-93.
18. Chen M, Cai E, Huang J, Yu P, Li K. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1126-34.
19. Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res. 2005;11(17):6190-7.
20. Takada N, Yano Y, Matsuda T, Otani S, Osugi H, Higashino M, et al. Expression of immunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. Cancer Lett. 1995;97(2):145-8.
21. Xu Z, Wang S, Wu M, Zeng W, Wang X, Dong Z. TGFbeta1 and HGF protein secretion by esophageal squamous epithelial cells and stromal fibroblasts in oesophageal carcinogenesis. Oncol Lett. 2013;6(2):401-6.
22. Han B, Liu J, Ma MJ, Zhao L. Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer. World J Gastroenterol. 2005;11(14):2188-92.
23. Sugiura K, Ozawa S, Kitagawa Y, Ueda M, Kitajima M. Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 2007;17(3):557-64.
24. Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, et al. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer. 2014;17(3):478-88.
25. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011;18(12):3316-23.
26. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19(5):329-37.
27. Diakowska D. Cytokines association with clinical and pathological changes in esophageal squamous cell carcinoma. Dis Markers. 2013;35(6):883-93.
28. Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116(16):3763-73.
29. Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32(5):385-91.
30. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882-7.
31. Boige V, Pignon J, Saint-Aubert B. Final results of a randomized trial comparing preoperative 5-Fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol (supplement). 2007;25(18 Suppl):15123.
32. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915-25.
33. Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 2008;98(6):1102-8.
34. Yuen MF, Norris S, Evans LW, Langley PG, Hughes RD. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol. 2002;37(2):233-8.
35. Ren P, Chen FF, Liu HY, Cui XL, Sun Y, Guan JL, et al. High serum levels of follistatin in patients with ovarian cancer. J Int Med Res. 2012;40(3):877-86.
36. Tumminello FM, Badalamenti G, Fulfaro F, Incorvaia L, Crescimanno M, Flandina C, et al. Serum follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis. 2010;27(8):549-55.
37. Blank S, Deck C, Dreikhausen L, Weichert W, Giese N, Falk C, et al. Angiogenic and growth factors in gastric cancer. J Surg Res. 2014 Nov 26. [Epub ahead of print].
38. Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. 2013;12:26.
39. Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer. 2001;92(3):663-9.
40. Mobius C, Freire J, Becker I, Feith M, Brucher BL, Hennig M, et al. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg. 2007;31(9):1768-72. discussion 1773-1764.
41. Diakowska D, Krzystek-Korpacka M, Markocka-Maczka K, Diakowski W, Matusiewicz M, Grabowski K. Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract. Cytokine. 2010;51(2):132-7.